menu
    • menu

    Company profile for Halo Pharmaceutical

    Noramco-PSE
    News
    Diversifying the Supply of Raw Materials

    12 Jun 2024

    // PRESS RELEASE

    Noramco Aligns with Purisys and Halo Pharma to Create Noramco Group

    15 Mar 2024

    // PRESS RELEASE

    Halo Labs Announces Closing of Second Tranche For Completion

    16 Oct 2019

    // BUSINESSWIRE

    DATA COMPILATION
    #PharmaFlow

    Noramco

    Contact Supplier

    Website

    INS 2025

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/4xXry1ozBsA

    EVENTS

    DIGITAL CONTENT

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Halo Pharma is a rapidly expanding contract development and manufacturing organization (CDMO) that delivers scientific expertise and comprehensive development and manufacturing services to a global client base. Operating from facilities in Whippany, New Jersey, USA, and Montreal, Quebec, Canada, Halo Pharma offers fully integrated capabilities across a wide range of dosage forms, including tablets, capsules, powders, liquids, creams, sterile and non-sterile ointments, and suppositories. The company is registered to handle these dosage forms under CI-CV DEA designations.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Halo PharmaceuticalUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    30 North Jefferson Road Whippany, NJ 07981 USA
    Telephone
    Telephone
    Client Email
    Email
    aambrosi@Noramco.com
    Client Website
    Website
    http://www.halopharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/halo-pharmaceutical-inc-/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Diversifying the Supply of Raw Materials
    Diversifying the Supply of Raw Materials

    12 Jun 2024

    // PRESS RELEASE

    https://www.noramco.com/2024/06/12/diversifying-the-supply-of-raw-materials/

    PRESS RELEASE
    12 Jun 2024
    Share Share
    Noramco Aligns with Purisys and Halo Pharma to Create Noramco Group
    Noramco Aligns with Purisys and Halo Pharma to Create Noramco Group

    15 Mar 2024

    // PRESS RELEASE

    https://www.noramco.com/2024/03/14/noramco-announces-strategic-alignment-with-purisys-and-halo-pharma/

    PRESS RELEASE
    15 Mar 2024
    Share Share
    Halo Labs Announces Closing of Second Tranche For Completion
    Halo Labs Announces Closing of Second Tranche For Completion

    16 Oct 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20191016005876/en

    BUSINESSWIRE
    16 Oct 2019
    Share Share
    Halo Labs Awarded Two Permanent Licenses at Second California Facility
    Halo Labs Awarded Two Permanent Licenses at Second California Facility

    26 Aug 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190826005197/en/Halo-Labs-Awarded-Permanent-Licenses-California-Facility

    BUSINESSWIRE
    26 Aug 2019
    Share Share
    Halo Pharma Canda Generic Acetaminophen;Oxycodone Hydrochloride Receives Approval in US
    Halo Pharma Canda Generic Acetaminophen;Oxycodone Hydrochloride Receives Approval in US

    20 Aug 2019

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207834

    FDA
    20 Aug 2019
    Share Share
    Cambrex closes on $425M deal for dosage-form CDMO Halo Pharma
    Cambrex closes on $425M deal for dosage-form CDMO Halo Pharma

    20 Sep 2018

    // Joseph Keenan FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/cambrex-closes-425m-deal-for-dosage-form-cdmo-halo-pharma

    Joseph Keenan FIERCE PHARMA
    20 Sep 2018
    Share Share

    Services

    Discover the service capabilities from this company

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search